FDA clears Neuralink to implant brain chip in second patient
According to a Wall Street Journal (WSJ) story published on Monday, the U.S. Food and Drug Administration (FDA) approved Neuralink, a business controlled by billionaire Elon Musk, to implant a brain chip in a second person after the firm promised to address an issue that occurred with the first patient.
Neuralink said earlier this month that tiny wires that were inserted into the first patient’s brain had moved. According to sources cited by Reuters last week, the corporation was aware that the wires may retract based on experiments conducted on animals.
According to the study, Neuralink plans to implant its device in a second patient in June and in ten individuals this year. Additionally, more than one thousand quadriplegics have registered for Neuralink’s patient registry.
According to the WSJ, Musk’s business also plans to apply to start comparable trials with regulators in Canada and Britain in the upcoming months.
A U.S. media story citing a source familiar with the business and a document said that it also aims to remedy the issue by introducing part of the device’s cables further into the brain.
According to Neuralink, the study makes use of a robot to surgically implant a brain-computer interface device in a part of the brain that regulates the intention to move.
